Synonym
DMP-543; DMP543; DMP 543; XR 543; XR-543; XR543;
IUPAC/Chemical Name
10,10-bis[(2-Fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone
InChi Key
MUJBUUDUXGDXLW-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2
SMILES Code
O=C1C2=C(C=CC=C2)C(CC3=CC(F)=NC=C3)(CC4=CC(F)=NC=C4)C5=CC=CC=C15
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
412.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Currò D. K+ channels as potential targets for the treatment of gastrointestinal motor disorders. Eur J Pharmacol. 2014 Jun 15;733:97-101. doi: 10.1016/j.ejphar.2014.03.049. PubMed PMID: 24726846.
2: Ipavec V, Martire M, Barrese V, Taglialatela M, Currò D. KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. Pharmacol Res. 2011 Oct;64(4):397-409. doi: 10.1016/j.phrs.2011.06.016. PubMed PMID: 21740972; PubMed Central PMCID: PMC3178758.
3: Chorvat RJ, Zaczek R, Brown BS. Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer's disease. Expert Opin Investig Drugs. 1998 Apr;7(4):499-518. PubMed PMID: 15991988.
4: Chen JG, Markovitz DA, Yang AY, Rabel SR, Pang J, Dolinsky O, Wu LS, Alasandro M. Degradation of a fluoropyridinyl drug in capsule formulation: degradant identification, proposed degradation mechanism, and formulation optimization. Pharm Dev Technol. 2000;5(4):561-70. PubMed PMID: 11109255.
5: Pesti JA, Huhn GF, Yin J, Xing Y, Fortunak JM, Earl RA. Efficient pyridinylmethyl functionalization: synthesis of 10, 10-Bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (DMP 543), an acetylcholine release enhancing agent. J Org Chem. 2000 Nov 17;65(23):7718-22. PubMed PMID: 11073571.
6: Earl RA, Zaczek R, Teleha CA, Fisher BN, Maciag CM, Marynowski ME, Logue AR, Tam SW, Tinker WJ, Huang SM, Chorvat RJ. 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem. 1998 Nov 5;41(23):4615-22. PubMed PMID: 9804701.
7: Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH, Earl RA. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther. 1998 May;285(2):724-30. PubMed PMID: 9580619.
